NCT05326308Recruiting
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 845 (estimated)
- First submitted
- 23 Mar 2022
- Start date
- 26 Apr 2022
- Primary completion date
- Aug 2028
- Lead sponsor
- iOMEDICO AG
- NCT number
- NCT05326308
What you commit to
- Study type: Observational
- Planned participants: 845
- From 26 Apr 2022 to the primary completion date, Aug 2028
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindications according to SmPC for patients with WM, CLL, MZL or FL
- Participation in an interventional clinical trial during zanubrutinib treatment.
Who the study is looking for
- Waldenström's macroglobulinemia (all treatment lines) OR
- Chronic lymphocytic leukemia (all treatment lines) OR
- Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy)
- Follicular lymphoma (≥3 treatment line)
- Signed and dated informed consent form
- Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL
- Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC
- Treatment decision before inclusion into this non-interventional study
- Age ≥18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsklinikum Salzburg, Klinik für Innere Medizin III Coordinator of this site? Confirm its status | Salzburg | Austria | Recruiting |
| Lübecker Onkologische Schwerpunktpraxis Coordinator of this site? Confirm its status | Lübeck | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.